NextCure, Inc.
General ticker "NXTC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $19.7M (TTM average)
NextCure, Inc. follows the US Stock Market performance with the rate: 30.8%.
Estimated limits based on current volatility of 24.7%: low 2.80$, high 4.63$
Factors to consider:
- Total employees count: 43 (-15.7%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Regulatory and compliance, Clinical trial success, Manufacturing risks, Reimbursement risks, Cybersecurity threats
- Current price 55.4% below estimated low
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.07$, 21.51$]
- 2026-12-31 to 2027-12-31 estimated range: [3.87$, 12.73$]
Financial Metrics affecting the NXTC estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 69.63 > 64.29
Short-term NXTC quotes
Long-term NXTC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $67.64MM | $59.75MM | $57.62MM |
| Operating Income | $-67.64MM | $-59.75MM | $-57.62MM |
| Non-Operating Income | $4.91MM | $4.09MM | $1.77MM |
| R&D Expense | $47.93MM | $41.49MM | $44.92MM |
| Income(Loss) | $-62.72MM | $-55.65MM | $-55.84MM |
| Net Income(Loss)* | $-62.72MM | $-55.65MM | $-55.84MM |
| Stockholders Equity | $114.42MM | $65.47MM | $34.94MM |
| Assets | $128.04MM | $80.86MM | $50.18MM |
| Operating Cash Flow | $-52.97MM | $-40.80MM | $-49.61MM |
| Capital expenditure | $0.82MM | $0.47MM | $0.00MM |
| Investing Cash Flow | $39.27MM | $55.31MM | $25.56MM |
| Financing Cash Flow | $0.15MM | $0.14MM | $22.31MM |
| Earnings Per Share** | $-27.04 | $-23.88 | $-19.65 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.